Jaafari Shokufe, Molaeinezhad Mitra, Tarrahi Mohammad J, Moosaei Mohsen R, Sahfiei Katayoun, Afshar Hamid
Department of Psychiatry, Behavioral Sciences Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Psychosomatic, Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2024 Oct 28;13:98. doi: 10.4103/abr.abr_202_23. eCollection 2024.
This study aimed to compare the efficacy of the two antidepressants, duloxetine and bupropion, on pelvic pain in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
This single-blind clinical trial was conducted on 68 CP/CPPS patients. The patients with CP/CPPS received either an extended-release formulation of 150 mg/day bupropion (bupropion group) or duloxetine 30 mg/day for 12 weeks (duloxetine group). The pain, depression (using the Hospital Anxiety and Depression Scale (HADS)), quality of life (QoL), and sexual dysfunction scores were evaluated and compared before the intervention and after 4, 12, and 16 weeks of intervention in both groups.
The pain score in the duloxetine group was significantly lower than the bupropion group after 12 and 16 weeks of intervention ( value <0.05). The mean HADS and QoL scores at baseline and after 4, 12, and 16 weeks of intervention had insignificant differences between the two groups ( value >0.05) but improved in both groups. After 4 and 12 weeks of intervention, sexual dysfunction scores in the duloxetine group were higher than those in the bupropion group ( value <0.05).
Depression and anxiety scores were significantly reduced in both groups. Sexual function was improved in the bupropion group compared with the duloxetine group, while pain scores improved significantly in the duloxetine group. Therefore, proposing the appropriate treatment based on the experienced complications of CP/CPPS is the key element of the management of these patients; however, further studies are required to compare the long-term effects of these two regimens on CP/CPPS patients' concerns.
本研究旨在比较两种抗抑郁药度洛西汀和安非他酮对慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPPS）患者盆腔疼痛的疗效。
对68例CP/CPPS患者进行了这项单盲临床试验。CP/CPPS患者接受150mg/天的安非他酮缓释制剂（安非他酮组）或30mg/天的度洛西汀治疗12周（度洛西汀组）。在干预前以及两组干预4周、12周和16周后，对疼痛、抑郁（使用医院焦虑抑郁量表（HADS））、生活质量（QoL）和性功能评分进行评估和比较。
干预12周和16周后，度洛西汀组的疼痛评分显著低于安非他酮组（ 值<0.05）。两组在基线时以及干预4周、12周和16周后的平均HADS和QoL评分无显著差异（ 值>0.05），但两组均有所改善。干预4周和12周后，度洛西汀组的性功能评分高于安非他酮组（ 值<0.05）。
两组的抑郁和焦虑评分均显著降低。与度洛西汀组相比，安非他酮组的性功能得到改善，而度洛西汀组的疼痛评分显著改善。因此，根据CP/CPPS患者所经历的并发症提出合适的治疗方案是这些患者管理的关键要素；然而，需要进一步研究来比较这两种治疗方案对CP/CPPS患者所关注问题的长期影响。
